Clinical Trial Update: A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors [EARLY_Phase 1]

View source ↗

Summary

This is an early-phase study evaluating allogeneic CD19/BCMA CAR-T cells for relapsed/refractory B-cell malignancies, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Multiple Myeloma

Drugs mentioned

• Allogeneic CD19/BCMA CAR-T cells

Snippet

Sponsor: YANRU WANG | Conditions: B Cell Lymphoma, Multiple Myeloma | EARLY_Phase 1 | Status: RECRUITING